ASTRAZENECA PLC ANNOUNCES BRILIQUE (TICAGRELOR) APPROVED IN EU FOR EXTENDED TREATMENT OF PATIENTS WITH HISTORY OF HEART ATTACK
February 19, 2016 02:05 ET
|
AstraZeneca PLC
Approval of new 60mg dose expands current indication to include long-term
treatment beyond the first year
AstraZeneca today announced that the European Commission has granted marketing
authorisation...
ASTRAZENECA PLC ANNOUNCES ZURAMPIC (LESINURAD) APPROVED IN THE EUROPEAN UNION FOR PATIENTS WITH GOUT
February 19, 2016 02:00 ET
|
AstraZeneca PLC
AstraZeneca today announced that the European Commission (EC) has granted
marketing authorisation for ZurampicTM(lesinurad) 200mg in combination with a
xanthine oxidase inhibitor (XOI) for the...
Durvalumab granted BTD by FDA for cancer patients
February 17, 2016 02:00 ET
|
AstraZeneca PLC
DURVALUMAB granted Breakthrough Therapy designation by US FDA for treatment of
patients with PD-L1 positive urothelial bladder cancer
AstraZeneca and MedImmune, its global biologics research and...
NEW EXTERNAL BOARD APPOINTMENT
February 16, 2016 03:08 ET
|
AstraZeneca PLC
AstraZeneca PLC
Listing Rule LR 9.6.14 R (2)
On 16 February 2016, Leif Johansson, Non-Executive Chairman of AstraZeneca PLC,
was elected as a new member to the Board of Directors of Autoliv, Inc.
A...
AstraZeneca Full-Year and Q4 2015 Results
February 04, 2016 02:00 ET
|
AstraZeneca PLC
4 February 2016
Full-Year and Q4 2015 Results
Financial Summary
+---------------------+------+----+------++-----+----+------+
| |FY 2015 ||Q4 2015 ...
Notice of Results
February 03, 2016 04:00 ET
|
AstraZeneca PLC
AstraZeneca PLC Full-Year and Q4 Results 2015
On Thursday, 4 February 2016, AstraZeneca PLC will release its full-year and Q4
2015 results at 07:00 GMT.
A presentation will take place at 12:00...
TAGRISSO approved in EU for cancer patients
February 03, 2016 02:00 ET
|
AstraZeneca PLC
TAGRISSO™ (osimertinib) approved in EU as first-in-class treatment for PATIENTS
WITH EGFR T790M mutation-positive metastatic non-small cell lung cancer
TAGRISSO™ is the first new medicine to be...
AZ Completes transaction with Acerta Pharma
February 02, 2016 04:31 ET
|
AstraZeneca PLC
ASTRAZENECA COMPLETES TRANSACTION FOR MAJORITY EQUITY STAKE INVESTMENT IN ACERTA
PHARMA
AstraZeneca today announced that it has completed the transaction to acquire a
majority equity stake in Acerta...
Lynparza Granted BTD in US for Prostate Cancer
January 28, 2016 02:02 ET
|
AstraZeneca PLC
LYNPARZA™ (Olaparib) granted Breakthrough Therapy Designation by US FDA for
treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant
Prostate Cancer
AstraZeneca today announced that...
Director/PDMR Shareholding
January 04, 2016 09:13 ET
|
AstraZeneca PLC
Transaction by Person Discharging Managerial Responsibilities
Disclosure Rule DTR 3.1.4
On 31 December 2015, Cori Bargmann, a Director of the Company notified us that,
on 30 December 2015, she became...